REFERENCES

Aoki, Toyohiko. “Current Status of Carcinogenicity Assessment of Peroxisome Proliferator-Activated Receptor Agonist by the US FDA and a Mode-of-Action Approach to the Carcinogenic Potential.” Journal of Toxicology Pathology, vol. 20, 2007, pp. 197–202.

De Castro, Mauricio, et al. “Determining the Prevalence of McArdle Disease from Gene Frequency by Analysis of next Generation Sequencing Data: McArdle Prevalence by NGS Data.” Genetic Medicine, vol. 17, no. 12, Dec. 2015, pp. 1002–1006.

Fan, Welwei, et al. “PPARδ Promotes Running Endurance by Preserving Glucose.” Cell Metabolism, vol. 25, no. 5, 2 May 2017, pp. 1186–1193.

Fedorova, Larisa V., et al. “Peroxisome Proliferator-Activated Receptor Agonist, HPP593, Prevents Renal Necrosis under Chronic Ischemia.” PLOS One, vol. 8, no. 5, 15 May 2013, pp. 1-13.

Gorman, Grainne S., et al. “Prevalence of Nuclear and Mitochondrial DNA Mutations Related to Adult Mitochondrial Disease.” Annals of Neurology, vol. 77, 4 Feb. 2015, pp. 753–759.

Han, Lu, et al. “PPARs: Regulators of Metabolism and as Therapeutic Targets in Cardiovascular Disease. Part1: PPAR-α” Future Cardiology, vol. 13, no. 3, 5 June 2017, pp. 259–278.

Hassani, Adam, et al. “Mitochondrial Myopathies: Development in Treatment.” Current Opinion in Neurology, vol. 23, no.5, Oct. 2010, pp. 459–465.

Jeppesen, Tina Dysgaard, et al. “Fat Metabolism During Exercise in Patients with Mitochondrial Disease.” Archives in Neurology, vol. 66, no. 3, 2009, pp. 365–370.

Kim, Kyung Ran, et al. “Caregiver’s Burden and Quality of Life in Mitochondrial Disease.” Pediatric Neurology, vol. 42, no. 4, April 2010, pp. 271–276.

Koman, J  C, and D  R Thorburn. “Turn up the Power – Pharmacological Activation of Mitochondrial Biogenesis in Mouse Models.” British Journal of Pharmacology, vol. 171, no.8, April 2014, pp. 1818–1836.

Kraja, Aldi T., et al. “Fenofibrate and Metabolic Syndrome.” Endocrine, Metabolic & Immune Disorders Drug Targets. vol. 10, no. 2, June 2010, pp. 138–148.

Lebovitz, Harold E. “Thiazolidinediones: The Forgotten Diabetes Medications.” Current Diabetes Reports. vol. 19, no. 151, 27 Nov. 2019, pp. 1-13.

Levy, Harvey L., et al. “Efficacy of Sapropterin Dihyrochloride (Tetrahydrobiopterin 6R-BH4) for Reduction of Phenylalanine Concentration in Patients with Phenylketonuria: A Phase III Randomized Placebo-Controlled Study.” Lancet, vol. 370, no. 9586, 11 Aug. 2007, pp. 504-510.

Lokken, Nicoline, et al. “Titrating a Modified Ketogenic Diet for Patients with McArdle Disease: A Pilot Study.” Journal of Inherited Metabolic Disease, vol. 43, no. 4, July 2020, pp. 778–786.

Merritt II, J. Lawrence, et al. “Fatty Acid Oxidation Disorders.” Annals of Translational Medicine, vol. 6, no. 24, Dec. 2018, pp. 473–486.

Mirza, Aga Zeeshan, et al. “Role of PPAR Receptor in Different Diseases and Their Ligands: Physiological Importance and Clinical Implications.” European Journal of Medicinal Chemistry, vol. 166, March 2019, pp. 502–513.

Narkar, Vihang A., et al. “AMPK and PPARδ Agonists Are Exercise Mimetics.” Cell, vol. 134, no. 3, 8 Aug. 2008, pp. 405–415.

Orsucci, Daniele, et al. “Quality of Life in Adult Patients with Mitochondrial Myopathy.” Neuroepidemiology, vol. 38, no. 3, May 2012, pp. 194–195.

Paoli, Antonio, et al. “Ketogenic Diet in Neuromuscular and Neurogenerative Diseases.” BioMed Research International, vol. 2014, 3 July 2014, pp.1-10.

Porchelli, Simone, et al. “Home-Based Aerobic Exercise Training Improves Skeletal Muscle Oxidative Metabolism in Patients with Metabolic Myopathies.” Journal of Applied Physiology, vol. 121, 12 Sept. 2016, pp. 699–708.

Steele, Hannah, et al. “Metabolic Effects of Bezafibrate in Mitochondrial Disease.” EMBO Molecular Medicine, vol. 12, no. 3, 6 March 2020, pp. 1–12.

Tarnopolsky, Mark A., and Sandeep Raha. “Mitochondrial Myopathies: Diagnosis, Exercise Intolerance, and Treatment Options.” Medicine & Science in Sports & Exercise, vol. 37, no. 12, 30 Nov. 2005, pp. 2086–2093.

Touyz, Rhian M., and Ernesto L. Schiffrin. “Peroxisome Proliferator-Activated Receptors in Vascular Biology-Molecular Mechanism and Clinical Implications.” Vascular Pharmacology, vol. 45, no. 1, July 2006, pp. 19–28.

Viskoper, Reuven J., et al. “McArdle’s Syndrome: The Reaction to a Fat-Rich Diet.” The American Journal of the Medical Sciences, vol. 269, no. 2, 28 Feb. 1975, pp. 217-221.

Vockley, Jerry, et al. “Results from a 78-Week, Single-Arm, Open-Label Phase 2 Study to Evaluate UX007 in Pediatric and Adult Patients with Severe Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD).” Journal of Inherited Metabolic Disease, vol. 42, no.1 Jan. 2019, pp. 169–177.